Skip to main content

satralizumab

Generic: satralizumab·Brand: Enspryng

satralizumab: 2 clinical trials tracked.

satralizumab evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about satralizumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 2 study sponsors

Related indications

No linked indication is available.

Clinical Trials (2)

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

NCT07010302·Phase 4·ENTA
Not yet recruiting

Primary endpoint: Time to adjudicated safety or tolerability failure

InterventionalRandomizeddouble160 targetStarted 2026-05Completion 2030-053 sites · Germany, United StatesMassachusetts General Hospital

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264·Phase 3·CRNX
Recruiting

Primary endpoint: Part 1: Proportion of Participants in NMDAR AIE Cohort With Modified Rankin Scale (mRS) Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 24

InterventionalRandomizedquadruple152 targetStarted 2022-09Completion 2029-1250 sites · Argentina, Austria, Brazil, China…Hoffmann-La Roche